<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340937</url>
  </required_header>
  <id_info>
    <org_study_id>V419-006</org_study_id>
    <nct_id>NCT01340937</nct_id>
  </id_info>
  <brief_title>A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)</brief_title>
  <official_title>A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq ™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether three manufacturing lots of V419 (PR5I) induce similar
      immune responses to all of the antigens contained in V419 when given concomitantly with
      Prevnar13™ and RotaTeq™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is partially Double-Blinded in that the participants' parents/guardians,
      investigator/study site personnel, and Sponsor's representatives will be blinded to the lot
      of V419 the participant is randomized to receive, but not to the participant's treatment
      group (V419 or control).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2011</start_date>
  <completion_date type="Actual">July 26, 2013</completion_date>
  <primary_completion_date type="Actual">December 18, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. The unit of measure is milli International Units/mL (mIU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Diphtheria Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. The unit of measure is International Units/mL (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Tetanus Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for anti-tetanus antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer for Antibodies to Poliovirus Type 1</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. The unit of measure is titer (reciprocal of highest dilution with neutralizing activity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer for Antibodies to Poliovirus Type 2</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer for Antibodies to Poliovirus Type 3</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for a titer &gt;=0.15 µg/mL and &gt;=1.0 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Hepatitis B Surface Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer &gt;=10 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Diphtheria Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer &gt;=0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Tetanus Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer &gt;=0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Pertactin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Fimbriae</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Poliovirus Type 1</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer &gt;=8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Poliovirus Type 2</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer &gt;=8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Poliovirus Type 3</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer &gt;=8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Toxin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Toxin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Pertactin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Fimbriae</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a multiplex electrochemiluminescence-based detection assay for serotype-specific pneumococcal polysaccharide antibodies. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions</measure>
    <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, &gt;5 cm. Grade 3 Solicited systemic reactions: Fever (Pyrexia), &gt;=39.5°C rectal; Vomiting, &gt;=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, &gt;3 hours; Drowsiness (Somnolence), Sleeping most of the time or difficult to wake up; Appetite lost, Refuses &gt;=3 feeds or refuses most feeds; Irritability, Inconsolable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevated Temperature by Severity</measure>
    <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
    <description>Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was &gt;=38.0°C.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2808</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>V419 Lot A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V419 Lot B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V419 Lot C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V419</intervention_name>
    <description>V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.</description>
    <arm_group_label>V419 Lot A</arm_group_label>
    <arm_group_label>V419 Lot B</arm_group_label>
    <arm_group_label>V419 Lot C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PENTACEL™</intervention_name>
    <description>PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group</description>
    <arm_group_label>V419 Lot A</arm_group_label>
    <arm_group_label>V419 Lot B</arm_group_label>
    <arm_group_label>V419 Lot C</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age</description>
    <arm_group_label>V419 Lot A</arm_group_label>
    <arm_group_label>V419 Lot B</arm_group_label>
    <arm_group_label>V419 Lot C</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq™</intervention_name>
    <description>RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age</description>
    <arm_group_label>V419 Lot A</arm_group_label>
    <arm_group_label>V419 Lot B</arm_group_label>
    <arm_group_label>V419 Lot C</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombivax HB vaccine</intervention_name>
    <description>Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Participant is a healthy infant

          -  Participant has received one dose of monovalent hepatitis B vaccine prior to 1 month
             of age

        Exclusion Criteria :

          -  Participant has received more than one dose of monovalent hepatitis B vaccine or
             hepatitis B based combination vaccine prior to study entry

          -  Participant has been vaccinated with any acellular pertussis or whole cell pertussis
             based combination vaccines, haemophilus influenzae type b conjugate, poliovirus,
             pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, measles, mumps,
             rubella, or varicella vaccines or any combination of the above

          -  Participant has had an illness with fever within 24 hours of study enrollment

          -  Participant was vaccinated with any non-study vaccine (i.e. inactivated, conjugated or
             live virus vaccine within 30 days prior to enrollment, except for inactivated
             influenza vaccine, which is permitted 15 days or more prior to enrollment

          -  Participant or his/her mother has hepatitis B surface antigen (HBsAg) seropositivity
             (by medical history)

          -  Participant has a history of haemophilus influenzae type B, hepatitis B, diphtheria,
             tetanus, pertussis, poliomyelitis, rotavirus, or pneumococcal infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Block SL, Klein NP, Sarpong K, Russell S, Fling J, Petrecz M, Flores S, Xu J, Liu G, Stek JE, Foglia G, Lee AW. Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants. Pediatr Infect Dis J. 2017 Feb;36(2):202-208. doi: 10.1097/INF.0000000000001405.</citation>
    <PMID>27846058</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>March 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2016</results_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Whooping Cough (pertussis)</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Hepatitis B infection</keyword>
  <keyword>Haemophilus influenzae type b infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The infant series of vaccinations were those administered at 2, 4, and 6 months of age; the toddler vaccinations were those administered at 15 months of age. The Interim Period is the time between the last vaccination of the infant series and the time of administration of the toddler vaccination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V419 Lot A</title>
          <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P2">
          <title>V419 Lot B</title>
          <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P3">
          <title>V419 Lot C</title>
          <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
          <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="800"/>
                <participants group_id="P2" count="797"/>
                <participants group_id="P3" count="809"/>
                <participants group_id="P4" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="742"/>
                <participants group_id="P2" count="737"/>
                <participants group_id="P3" count="753"/>
                <participants group_id="P4" count="370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other protocol criterion not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Interim Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="742"/>
                <participants group_id="P2" count="737"/>
                <participants group_id="P3" count="753"/>
                <participants group_id="P4" count="370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="675"/>
                <participants group_id="P2" count="658"/>
                <participants group_id="P3" count="669"/>
                <participants group_id="P4" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3: Toddler Vaccinations</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="675"/>
                <participants group_id="P2" count="658"/>
                <participants group_id="P3" count="669"/>
                <participants group_id="P4" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="666"/>
                <participants group_id="P2" count="641"/>
                <participants group_id="P3" count="660"/>
                <participants group_id="P4" count="319"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problem</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V419 Lot A</title>
          <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B2">
          <title>V419 Lot B</title>
          <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B3">
          <title>V419 Lot C</title>
          <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
          <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="800"/>
            <count group_id="B2" value="797"/>
            <count group_id="B3" value="809"/>
            <count group_id="B4" value="402"/>
            <count group_id="B5" value="2808"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="6.7"/>
                    <measurement group_id="B2" value="64.4" spread="6.2"/>
                    <measurement group_id="B3" value="64.7" spread="6.6"/>
                    <measurement group_id="B4" value="64.3" spread="6.6"/>
                    <measurement group_id="B5" value="64.5" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="380"/>
                    <measurement group_id="B4" value="215"/>
                    <measurement group_id="B5" value="1338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="423"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="429"/>
                    <measurement group_id="B4" value="187"/>
                    <measurement group_id="B5" value="1470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen</title>
        <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen</title>
          <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="604"/>
                <count group_id="O2" value="596"/>
                <count group_id="O3" value="595"/>
                <count group_id="O4" value="288"/>
                <count group_id="O5" value="1795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" lower_limit="4.88" upper_limit="6.21"/>
                    <measurement group_id="O2" value="6.10" lower_limit="5.38" upper_limit="6.92"/>
                    <measurement group_id="O3" value="6.59" lower_limit="5.80" upper_limit="7.47"/>
                    <measurement group_id="O4" value="3.76" lower_limit="3.11" upper_limit="4.55"/>
                    <measurement group_id="O5" value="6.05" lower_limit="5.63" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the Geometric Mean Concentration (GMC) ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen</title>
        <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for a titer &gt;=0.15 µg/mL and &gt;=1.0 µg/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen</title>
          <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for a titer &gt;=0.15 µg/mL and &gt;=1.0 µg/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="604"/>
                <count group_id="O2" value="596"/>
                <count group_id="O3" value="595"/>
                <count group_id="O4" value="288"/>
                <count group_id="O5" value="1795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Titer &gt;=1 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.75" lower_limit="83.79" upper_limit="89.36"/>
                    <measurement group_id="O2" value="87.25" lower_limit="84.30" upper_limit="89.82"/>
                    <measurement group_id="O3" value="88.40" lower_limit="85.55" upper_limit="90.86"/>
                    <measurement group_id="O4" value="79.51" lower_limit="74.39" upper_limit="84.02"/>
                    <measurement group_id="O5" value="87.47" lower_limit="85.84" upper_limit="88.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer &gt;=0.15 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.01" lower_limit="97.85" upper_limit="99.63"/>
                    <measurement group_id="O2" value="98.32" lower_limit="96.94" upper_limit="99.19"/>
                    <measurement group_id="O3" value="97.82" lower_limit="96.29" upper_limit="98.83"/>
                    <measurement group_id="O4" value="96.18" lower_limit="93.27" upper_limit="98.08"/>
                    <measurement group_id="O5" value="98.38" lower_limit="97.69" upper_limit="98.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence for titer &gt;=1 µg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.31</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Equivalence for titer &gt;=1 µg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>-1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.38</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Equivalence for titer &gt;=1 µg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.89</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority for titer &gt;=1 µg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>7.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.38</ci_lower_limit>
            <ci_upper_limit>13.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority for titer &gt;=0.15 µg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>2.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>5.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen</title>
        <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. The unit of measure is milli International Units/mL (mIU/mL).</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen</title>
          <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. The unit of measure is milli International Units/mL (mIU/mL).</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="580"/>
                <count group_id="O4" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1195.96" lower_limit="1081.62" upper_limit="1322.39"/>
                    <measurement group_id="O2" value="1376.86" lower_limit="1264.74" upper_limit="1498.92"/>
                    <measurement group_id="O3" value="1414.52" lower_limit="1297.52" upper_limit="1542.06"/>
                    <measurement group_id="O4" value="609.08" lower_limit="515.29" upper_limit="719.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Diphtheria Toxin</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. The unit of measure is International Units/mL (IU/mL).</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Diphtheria Toxin</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. The unit of measure is International Units/mL (IU/mL).</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="625"/>
                <count group_id="O3" value="618"/>
                <count group_id="O4" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.34" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.33" upper_limit="0.40"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.34" upper_limit="0.41"/>
                    <measurement group_id="O4" value="0.40" lower_limit="0.35" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Tetanus Toxin</title>
        <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for anti-tetanus antibodies.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Tetanus Toxin</title>
          <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for anti-tetanus antibodies.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="609"/>
                <count group_id="O3" value="612"/>
                <count group_id="O4" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="1.51" upper_limit="1.67"/>
                    <measurement group_id="O2" value="1.63" lower_limit="1.55" upper_limit="1.71"/>
                    <measurement group_id="O3" value="1.55" lower_limit="1.48" upper_limit="1.63"/>
                    <measurement group_id="O4" value="0.89" lower_limit="0.81" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="647"/>
                <count group_id="O2" value="634"/>
                <count group_id="O3" value="622"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="1903"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.83" lower_limit="95.98" upper_limit="105.91"/>
                    <measurement group_id="O2" value="96.82" lower_limit="92.10" upper_limit="101.79"/>
                    <measurement group_id="O3" value="98.52" lower_limit="93.84" upper_limit="103.43"/>
                    <measurement group_id="O4" value="82.45" lower_limit="77.26" upper_limit="87.98"/>
                    <measurement group_id="O5" value="98.72" lower_limit="95.96" upper_limit="101.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Secondary analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="644"/>
                <count group_id="O2" value="631"/>
                <count group_id="O3" value="628"/>
                <count group_id="O4" value="312"/>
                <count group_id="O5" value="1903"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.98" lower_limit="41.45" upper_limit="46.66"/>
                    <measurement group_id="O2" value="49.19" lower_limit="46.52" upper_limit="52.02"/>
                    <measurement group_id="O3" value="56.93" lower_limit="53.73" upper_limit="60.31"/>
                    <measurement group_id="O4" value="73.25" lower_limit="67.94" upper_limit="78.97"/>
                    <measurement group_id="O5" value="49.70" lower_limit="48.06" upper_limit="51.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Secondary analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>0.419</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="611"/>
                <count group_id="O4" value="303"/>
                <count group_id="O5" value="1859"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.30" lower_limit="47.46" upper_limit="55.44"/>
                    <measurement group_id="O2" value="52.32" lower_limit="47.85" upper_limit="57.21"/>
                    <measurement group_id="O3" value="54.78" lower_limit="50.33" upper_limit="59.61"/>
                    <measurement group_id="O4" value="50.96" lower_limit="45.38" upper_limit="57.21"/>
                    <measurement group_id="O5" value="52.76" lower_limit="50.27" upper_limit="55.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Secondary analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="641"/>
                <count group_id="O2" value="632"/>
                <count group_id="O3" value="623"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="1896"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.78" lower_limit="213.87" upper_limit="244.73"/>
                    <measurement group_id="O2" value="286.74" lower_limit="268.86" upper_limit="305.81"/>
                    <measurement group_id="O3" value="283.28" lower_limit="264.52" upper_limit="303.36"/>
                    <measurement group_id="O4" value="175.65" lower_limit="159.14" upper_limit="193.87"/>
                    <measurement group_id="O5" value="264.61" lower_limit="254.54" upper_limit="275.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot B)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot A/Lot C)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMC ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMC Ratio (Lot B/Lot C)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>GMC ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Secondary analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer for Antibodies to Poliovirus Type 1</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. The unit of measure is titer (reciprocal of highest dilution with neutralizing activity).</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer for Antibodies to Poliovirus Type 1</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. The unit of measure is titer (reciprocal of highest dilution with neutralizing activity).</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="632"/>
                <count group_id="O3" value="628"/>
                <count group_id="O4" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.77" lower_limit="533.82" upper_limit="629.68"/>
                    <measurement group_id="O2" value="684.68" lower_limit="628.40" upper_limit="746.01"/>
                    <measurement group_id="O3" value="666.18" lower_limit="612.30" upper_limit="724.79"/>
                    <measurement group_id="O4" value="269.95" lower_limit="232.21" upper_limit="313.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the Geometric Mean Titer (GMT) ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot A/Lot B)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot A/Lot C)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot B/Lot C)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer for Antibodies to Poliovirus Type 2</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer for Antibodies to Poliovirus Type 2</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="632"/>
                <count group_id="O3" value="633"/>
                <count group_id="O4" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1212.40" lower_limit="1116.40" upper_limit="1316.65"/>
                    <measurement group_id="O2" value="1276.56" lower_limit="1172.86" upper_limit="1389.43"/>
                    <measurement group_id="O3" value="1359.78" lower_limit="1248.13" upper_limit="1481.42"/>
                    <measurement group_id="O4" value="846.14" lower_limit="751.81" upper_limit="952.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot A/Lot B)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot A/Lot C)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot B/Lot C)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer for Antibodies to Poliovirus Type 3</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer for Antibodies to Poliovirus Type 3</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="625"/>
                <count group_id="O3" value="625"/>
                <count group_id="O4" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="901.70" lower_limit="819.52" upper_limit="992.12"/>
                    <measurement group_id="O2" value="851.34" lower_limit="772.96" upper_limit="937.66"/>
                    <measurement group_id="O3" value="825.31" lower_limit="746.52" upper_limit="912.42"/>
                    <measurement group_id="O4" value="784.24" lower_limit="682.28" upper_limit="901.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot A/Lot B)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot A/Lot C)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% confidence intervals of the GMT ratio are within the margin 0.67 to 1.5</non_inferiority_desc>
            <param_type>GMT Ratio (Lot B/Lot C)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>GMT ratio was adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Hepatitis B Surface Antigen</title>
        <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer &gt;=10 mIU/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Hepatitis B Surface Antigen</title>
          <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer &gt;=10 mIU/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="580"/>
                <count group_id="O4" value="286"/>
                <count group_id="O5" value="1767"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.66" lower_limit="98.78" upper_limit="99.96"/>
                    <measurement group_id="O2" value="100.00" lower_limit="99.39" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="99.37" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.95" lower_limit="96.97" upper_limit="99.78"/>
                    <measurement group_id="O5" value="99.89" lower_limit="99.59" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Diphtheria Toxin</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer &gt;=0.1 IU/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Diphtheria Toxin</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer &gt;=0.1 IU/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="625"/>
                <count group_id="O3" value="618"/>
                <count group_id="O4" value="301"/>
                <count group_id="O5" value="1865"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.05" lower_limit="82.00" upper_limit="87.76"/>
                    <measurement group_id="O2" value="84.80" lower_limit="81.74" upper_limit="87.52"/>
                    <measurement group_id="O3" value="86.41" lower_limit="83.45" upper_limit="89.01"/>
                    <measurement group_id="O4" value="87.71" lower_limit="83.46" upper_limit="91.20"/>
                    <measurement group_id="O5" value="85.42" lower_limit="83.73" upper_limit="86.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.74</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.26</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>-1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.56</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>-2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.02</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Tetanus Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer &gt;=0.1 IU/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Tetanus Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer &gt;=0.1 IU/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="609"/>
                <count group_id="O3" value="612"/>
                <count group_id="O4" value="300"/>
                <count group_id="O5" value="1843"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.84" lower_limit="99.11" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="99.40" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="99.40" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.67" lower_limit="96.62" upper_limit="99.64"/>
                    <measurement group_id="O5" value="99.95" lower_limit="99.70" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="596"/>
                <count group_id="O2" value="585"/>
                <count group_id="O3" value="580"/>
                <count group_id="O4" value="289"/>
                <count group_id="O5" value="1761"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.33" lower_limit="98.29" upper_limit="99.82"/>
                    <measurement group_id="O2" value="97.61" lower_limit="96.02" upper_limit="98.69"/>
                    <measurement group_id="O3" value="98.97" lower_limit="97.76" upper_limit="99.62"/>
                    <measurement group_id="O4" value="97.92" lower_limit="95.54" upper_limit="99.23"/>
                    <measurement group_id="O5" value="98.64" lower_limit="97.98" upper_limit="99.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>-1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>3.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="620"/>
                <count group_id="O2" value="615"/>
                <count group_id="O3" value="601"/>
                <count group_id="O4" value="304"/>
                <count group_id="O5" value="1836"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.97" lower_limit="82.98" upper_limit="88.61"/>
                    <measurement group_id="O2" value="87.32" lower_limit="84.43" upper_limit="89.84"/>
                    <measurement group_id="O3" value="89.02" lower_limit="86.24" upper_limit="91.40"/>
                    <measurement group_id="O4" value="92.11" lower_limit="88.48" upper_limit="94.88"/>
                    <measurement group_id="O5" value="87.42" lower_limit="85.81" upper_limit="88.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.17</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>-3.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.79</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>-1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.37</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>-4.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.73</ci_lower_limit>
            <ci_upper_limit>-0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="590"/>
                <count group_id="O2" value="574"/>
                <count group_id="O3" value="560"/>
                <count group_id="O4" value="286"/>
                <count group_id="O5" value="1724"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.19" lower_limit="77.79" upper_limit="84.26"/>
                    <measurement group_id="O2" value="78.40" lower_limit="74.80" upper_limit="81.70"/>
                    <measurement group_id="O3" value="78.75" lower_limit="75.13" upper_limit="82.07"/>
                    <measurement group_id="O4" value="76.22" lower_limit="70.86" upper_limit="81.04"/>
                    <measurement group_id="O5" value="79.47" lower_limit="77.48" upper_limit="81.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>7.39</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>2.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>7.06</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.14</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>3.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>8.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="611"/>
                <count group_id="O3" value="594"/>
                <count group_id="O4" value="298"/>
                <count group_id="O5" value="1818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.95" lower_limit="84.02" upper_limit="89.51"/>
                    <measurement group_id="O2" value="91.00" lower_limit="88.44" upper_limit="93.15"/>
                    <measurement group_id="O3" value="91.08" lower_limit="88.49" upper_limit="93.25"/>
                    <measurement group_id="O4" value="86.91" lower_limit="82.55" upper_limit="90.53"/>
                    <measurement group_id="O5" value="89.66" lower_limit="88.17" upper_limit="91.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>-4.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.69</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>-4.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.75</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -10% and 10%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.32</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>2.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>7.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Poliovirus Type 1</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer &gt;=8.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Poliovirus Type 1</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer &gt;=8.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="632"/>
                <count group_id="O3" value="628"/>
                <count group_id="O4" value="307"/>
                <count group_id="O5" value="1890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.42" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="99.42" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="99.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="99.35" lower_limit="97.67" upper_limit="99.92"/>
                    <measurement group_id="O5" value="100.00" lower_limit="99.81" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Poliovirus Type 2</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer &gt;=8.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Poliovirus Type 2</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer &gt;=8.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="632"/>
                <count group_id="O3" value="633"/>
                <count group_id="O4" value="307"/>
                <count group_id="O5" value="1895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.42" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="99.42" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="99.42" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="98.81" upper_limit="100.00"/>
                    <measurement group_id="O5" value="100.00" lower_limit="99.81" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Poliovirus Type 3</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer &gt;=8.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Poliovirus Type 3</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer &gt;=8.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="625"/>
                <count group_id="O3" value="625"/>
                <count group_id="O4" value="304"/>
                <count group_id="O5" value="1874"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.41" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="99.41" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="99.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="99.67" lower_limit="98.18" upper_limit="99.99"/>
                    <measurement group_id="O5" value="100.00" lower_limit="99.80" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot B)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot A - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence requires that the 2-sided 95% Confidence Intervals of the response rate difference are between -5% and 5%</non_inferiority_desc>
            <param_type>Response Rate Difference (Lot B - Lot C)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Response rate difference was stratified by brand of birth dose of Hepatitis B vaccine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1744"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="584"/>
                <count group_id="O4" value="572"/>
                <count group_id="O5" value="588"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.61" lower_limit="106.92" upper_limit="114.42"/>
                    <measurement group_id="O2" value="102.82" lower_limit="93.70" upper_limit="112.82"/>
                    <measurement group_id="O3" value="110.41" lower_limit="104.08" upper_limit="117.14"/>
                    <measurement group_id="O4" value="110.62" lower_limit="104.14" upper_limit="117.51"/>
                    <measurement group_id="O5" value="110.79" lower_limit="104.65" upper_limit="117.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Analysis of Covariance</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1742"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="583"/>
                <count group_id="O4" value="572"/>
                <count group_id="O5" value="587"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.30" lower_limit="102.73" upper_limit="110.00"/>
                    <measurement group_id="O2" value="121.00" lower_limit="110.19" upper_limit="132.87"/>
                    <measurement group_id="O3" value="101.81" lower_limit="95.85" upper_limit="108.14"/>
                    <measurement group_id="O4" value="104.70" lower_limit="98.66" upper_limit="111.12"/>
                    <measurement group_id="O5" value="112.60" lower_limit="106.27" upper_limit="119.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1746"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="584"/>
                <count group_id="O4" value="573"/>
                <count group_id="O5" value="589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.51" lower_limit="100.14" upper_limit="109.07"/>
                    <measurement group_id="O2" value="142.32" lower_limit="126.68" upper_limit="159.89"/>
                    <measurement group_id="O3" value="94.26" lower_limit="87.23" upper_limit="101.85"/>
                    <measurement group_id="O4" value="108.69" lower_limit="101.41" upper_limit="116.51"/>
                    <measurement group_id="O5" value="111.42" lower_limit="103.44" upper_limit="120.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1746"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="584"/>
                <count group_id="O4" value="573"/>
                <count group_id="O5" value="589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.04" lower_limit="433.21" upper_limit="469.60"/>
                    <measurement group_id="O2" value="337.79" lower_limit="299.43" upper_limit="381.05"/>
                    <measurement group_id="O3" value="409.37" lower_limit="379.54" upper_limit="441.54"/>
                    <measurement group_id="O4" value="475.65" lower_limit="444.85" upper_limit="508.59"/>
                    <measurement group_id="O5" value="471.52" lower_limit="441.30" upper_limit="503.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1616"/>
                <count group_id="O2" value="254"/>
                <count group_id="O3" value="535"/>
                <count group_id="O4" value="531"/>
                <count group_id="O5" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.51" lower_limit="97.80" upper_limit="99.05"/>
                    <measurement group_id="O2" value="98.43" lower_limit="96.02" upper_limit="99.57"/>
                    <measurement group_id="O3" value="99.25" lower_limit="98.10" upper_limit="99.80"/>
                    <measurement group_id="O4" value="98.12" lower_limit="96.56" upper_limit="99.09"/>
                    <measurement group_id="O5" value="98.18" lower_limit="96.68" upper_limit="99.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1669"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="559"/>
                <count group_id="O4" value="550"/>
                <count group_id="O5" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.33" lower_limit="94.20" upper_limit="96.29"/>
                    <measurement group_id="O2" value="95.40" lower_limit="92.11" upper_limit="97.60"/>
                    <measurement group_id="O3" value="96.06" lower_limit="94.10" upper_limit="97.52"/>
                    <measurement group_id="O4" value="94.36" lower_limit="92.09" upper_limit="96.14"/>
                    <measurement group_id="O5" value="95.54" lower_limit="93.48" upper_limit="97.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>3.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1608"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="539"/>
                <count group_id="O4" value="530"/>
                <count group_id="O5" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.16" lower_limit="90.74" upper_limit="93.43"/>
                    <measurement group_id="O2" value="91.09" lower_limit="86.92" upper_limit="94.26"/>
                    <measurement group_id="O3" value="91.28" lower_limit="88.57" upper_limit="93.52"/>
                    <measurement group_id="O4" value="92.08" lower_limit="89.44" upper_limit="94.23"/>
                    <measurement group_id="O5" value="93.14" lower_limit="90.66" upper_limit="95.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.13</ci_lower_limit>
            <ci_upper_limit>5.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1664"/>
                <count group_id="O2" value="264"/>
                <count group_id="O3" value="556"/>
                <count group_id="O4" value="549"/>
                <count group_id="O5" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.97" lower_limit="91.63" upper_limit="94.15"/>
                    <measurement group_id="O2" value="90.15" lower_limit="85.90" upper_limit="93.47"/>
                    <measurement group_id="O3" value="91.91" lower_limit="89.32" upper_limit="94.04"/>
                    <measurement group_id="O4" value="94.17" lower_limit="91.87" upper_limit="95.98"/>
                    <measurement group_id="O5" value="92.84" lower_limit="90.38" upper_limit="94.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (Comb - Ctrl)</param_type>
            <param_value>3.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>7.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes</title>
        <description>Participant serum samples were collected for testing with a multiplex electrochemiluminescence-based detection assay for serotype-specific pneumococcal polysaccharide antibodies. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>V419 Lot A</title>
            <description>V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>V419 Lot B</title>
            <description>V419 (Lot B) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O5">
            <title>V419 Lot C</title>
            <description>V419 (Lot C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes</title>
          <description>Participant serum samples were collected for testing with a multiplex electrochemiluminescence-based detection assay for serotype-specific pneumococcal polysaccharide antibodies. Analysis for this outcome included only non-inferiority of V419 Lots A, B, and C Combined versus Control.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1256"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="414"/>
                <count group_id="O4" value="419"/>
                <count group_id="O5" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=1256, 191, 414, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" lower_limit="1.38" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.39" upper_limit="1.73"/>
                    <measurement group_id="O3" value="1.47" lower_limit="1.36" upper_limit="1.59"/>
                    <measurement group_id="O4" value="1.40" lower_limit="1.30" upper_limit="1.51"/>
                    <measurement group_id="O5" value="1.44" lower_limit="1.34" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=1255, 191, 414, 418, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.46" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.45" upper_limit="0.56"/>
                    <measurement group_id="O3" value="0.48" lower_limit="0.45" upper_limit="0.51"/>
                    <measurement group_id="O4" value="0.48" lower_limit="0.44" upper_limit="0.51"/>
                    <measurement group_id="O5" value="0.47" lower_limit="0.44" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=1255, 189, 414, 418, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="1.17" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.22" lower_limit="1.10" upper_limit="1.35"/>
                    <measurement group_id="O3" value="1.27" lower_limit="1.18" upper_limit="1.36"/>
                    <measurement group_id="O4" value="1.16" lower_limit="1.08" upper_limit="1.25"/>
                    <measurement group_id="O5" value="1.24" lower_limit="1.16" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=1256, 191, 414, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.42" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.41" upper_limit="1.82"/>
                    <measurement group_id="O3" value="1.49" lower_limit="1.36" upper_limit="1.64"/>
                    <measurement group_id="O4" value="1.49" lower_limit="1.36" upper_limit="1.63"/>
                    <measurement group_id="O5" value="1.49" lower_limit="1.36" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=1251, 191, 412, 417, 422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="2.45" upper_limit="2.69"/>
                    <measurement group_id="O2" value="2.96" lower_limit="2.64" upper_limit="3.32"/>
                    <measurement group_id="O3" value="2.49" lower_limit="2.29" upper_limit="2.71"/>
                    <measurement group_id="O4" value="2.66" lower_limit="2.45" upper_limit="2.90"/>
                    <measurement group_id="O5" value="2.55" lower_limit="2.36" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=1255, 190, 414, 419, 422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.94" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.29" lower_limit="1.07" upper_limit="1.54"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.88" upper_limit="1.14"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.89" upper_limit="1.15"/>
                    <measurement group_id="O5" value="1.01" lower_limit="0.89" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=1256, 191, 414, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.64" upper_limit="2.85"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.77" upper_limit="3.41"/>
                    <measurement group_id="O3" value="2.78" lower_limit="2.60" upper_limit="2.97"/>
                    <measurement group_id="O4" value="2.75" lower_limit="2.58" upper_limit="2.94"/>
                    <measurement group_id="O5" value="2.70" lower_limit="2.53" upper_limit="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=1256, 189, 414, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="1.29" upper_limit="1.41"/>
                    <measurement group_id="O2" value="1.35" lower_limit="1.19" upper_limit="1.52"/>
                    <measurement group_id="O3" value="1.40" lower_limit="1.29" upper_limit="1.52"/>
                    <measurement group_id="O4" value="1.30" lower_limit="1.21" upper_limit="1.41"/>
                    <measurement group_id="O5" value="1.35" lower_limit="1.25" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=1256, 191, 414, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="4.48" upper_limit="5.01"/>
                    <measurement group_id="O2" value="4.83" lower_limit="4.26" upper_limit="5.48"/>
                    <measurement group_id="O3" value="4.91" lower_limit="4.45" upper_limit="5.42"/>
                    <measurement group_id="O4" value="4.85" lower_limit="4.42" upper_limit="5.32"/>
                    <measurement group_id="O5" value="4.47" lower_limit="4.05" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=1253, 191, 413, 418, 422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="1.55" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.82" lower_limit="1.62" upper_limit="2.03"/>
                    <measurement group_id="O3" value="1.69" lower_limit="1.57" upper_limit="1.82"/>
                    <measurement group_id="O4" value="1.62" lower_limit="1.51" upper_limit="1.75"/>
                    <measurement group_id="O5" value="1.55" lower_limit="1.44" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=1254, 191, 413, 418, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.53" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.75" lower_limit="1.55" upper_limit="1.99"/>
                    <measurement group_id="O3" value="1.67" lower_limit="1.55" upper_limit="1.81"/>
                    <measurement group_id="O4" value="1.52" lower_limit="1.41" upper_limit="1.65"/>
                    <measurement group_id="O5" value="1.61" lower_limit="1.49" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=1256, 191, 414, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" lower_limit="2.10" upper_limit="2.27"/>
                    <measurement group_id="O2" value="2.26" lower_limit="2.03" upper_limit="2.50"/>
                    <measurement group_id="O3" value="2.24" lower_limit="2.09" upper_limit="2.41"/>
                    <measurement group_id="O4" value="2.11" lower_limit="1.97" upper_limit="2.26"/>
                    <measurement group_id="O5" value="2.19" lower_limit="2.05" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=1254, 190, 412, 419, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="1.04" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.20" lower_limit="1.04" upper_limit="1.38"/>
                    <measurement group_id="O3" value="1.16" lower_limit="1.05" upper_limit="1.28"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.97" upper_limit="1.18"/>
                    <measurement group_id="O5" value="1.07" lower_limit="0.97" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 6A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>0.055</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 7F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 19A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pneumococcal Serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (Combined/Control)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions</title>
        <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, &gt;5 cm. Grade 3 Solicited systemic reactions: Fever (Pyrexia), &gt;=39.5°C rectal; Vomiting, &gt;=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, &gt;3 hours; Drowsiness (Somnolence), Sleeping most of the time or difficult to wake up; Appetite lost, Refuses &gt;=3 feeds or refuses most feeds; Irritability, Inconsolable.</description>
        <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in these analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up. This outcome applied only to V419 Lots A, B, and C Combined and Control; therefore, data for the individual V419 lots are not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions</title>
          <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, &gt;5 cm. Grade 3 Solicited systemic reactions: Fever (Pyrexia), &gt;=39.5°C rectal; Vomiting, &gt;=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, &gt;3 hours; Drowsiness (Somnolence), Sleeping most of the time or difficult to wake up; Appetite lost, Refuses &gt;=3 feeds or refuses most feeds; Irritability, Inconsolable.</description>
          <population>Participants included in these analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up. This outcome applied only to V419 Lots A, B, and C Combined and Control; therefore, data for the individual V419 lots are not reported.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
                <count group_id="O2" value="2390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                    <measurement group_id="O2" value="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8"/>
                    <measurement group_id="O2" value="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2"/>
                    <measurement group_id="O2" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevated Temperature by Severity</title>
        <description>Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was &gt;=38.0°C.</description>
        <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in this analyses were All Subjects as Treated population defined as all vaccinated participants with safety follow up and temperature data. This outcome applied only to V419 Lots A, B, and C Combined and Control; therefore, data for the individual V419 lots are not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>V419 Lots A, B, and C Combined</title>
            <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Temperature by Severity</title>
          <description>Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was &gt;=38.0°C.</description>
          <population>Participants included in this analyses were All Subjects as Treated population defined as all vaccinated participants with safety follow up and temperature data. This outcome applied only to V419 Lots A, B, and C Combined and Control; therefore, data for the individual V419 lots are not reported.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2308"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All routes &lt;38.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="1.38" upper_limit="1.50"/>
                    <measurement group_id="O2" value="64.6" lower_limit="1.39" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All routes &gt;=38.0°C and &lt;38.5°C, mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="0.46" upper_limit="0.50"/>
                    <measurement group_id="O2" value="23.3" lower_limit="0.45" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All routes &gt;=38.5°C and &lt;39.5°C, moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="1.17" upper_limit="1.27"/>
                    <measurement group_id="O2" value="10.8" lower_limit="1.10" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All routes &gt;=39.5°C, severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.42" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.41" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &lt;38.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="2.45" upper_limit="2.69"/>
                    <measurement group_id="O2" value="59.0" lower_limit="2.64" upper_limit="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &gt;=38.0°C and &lt;38.5°C, mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="0.94" upper_limit="1.09"/>
                    <measurement group_id="O2" value="23.0" lower_limit="1.07" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &gt;=38.5°C and &lt;39.5°C, moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="2.64" upper_limit="2.85"/>
                    <measurement group_id="O2" value="10.6" lower_limit="2.77" upper_limit="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &gt;=39.5°C, severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.29" upper_limit="1.41"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.19" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference, all routes &lt;38.0°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.8</ci_lower_limit>
            <ci_upper_limit>-8.4</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference, all routes &gt;=38°C and &lt;38.5°</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference, all routes &gt;=38.5°C and &lt;39.5°</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference, all routes &gt;=39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference; rectal &lt;38.0°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.6</ci_lower_limit>
            <ci_upper_limit>-5.9</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference; rectal &gt;=38.0°C and &lt;38.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference, rectal &gt;=38.5°C and &lt;39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated Difference, rectal &gt;=39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence interval is based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: up to 6 months after vaccination 3 (the last infant vaccination) and up to 15 days after vaccination 4 (the toddler vaccination); Vaccine-related SAEs and deaths: up to Month 16 (duration of the study); Other AEs: up to 15 days after any vaccination</time_frame>
      <desc>The All Subjects as Treated population included all randomized participants who received at least one dose of study vaccine and had safety follow-up. For safety analysis, participants who received the 3 V419 lots were combined.</desc>
      <group_list>
        <group group_id="E1">
          <title>V419 Lots A, B, and C Combined</title>
          <description>V419 (Lot A, B, or C) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="2390"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Gatroenteritis viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2259" subjects_at_risk="2390"/>
                <counts group_id="E2" subjects_affected="371" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="215" subjects_affected="192" subjects_at_risk="2390"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1139" subjects_affected="723" subjects_at_risk="2390"/>
                <counts group_id="E2" events="171" subjects_affected="110" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="4597" subjects_affected="1867" subjects_at_risk="2390"/>
                <counts group_id="E2" events="763" subjects_affected="300" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="5595" subjects_affected="1993" subjects_at_risk="2390"/>
                <counts group_id="E2" events="925" subjects_affected="324" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2302" subjects_affected="1285" subjects_at_risk="2390"/>
                <counts group_id="E2" events="274" subjects_affected="174" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Injection-site bruising</sub_title>
                <counts group_id="E1" events="174" subjects_affected="128" subjects_at_risk="2390"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="5189" subjects_affected="1302" subjects_at_risk="2390"/>
                <counts group_id="E2" events="911" subjects_affected="203" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="8854" subjects_affected="1883" subjects_at_risk="2390"/>
                <counts group_id="E2" events="1815" subjects_affected="314" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="3652" subjects_affected="1073" subjects_at_risk="2390"/>
                <counts group_id="E2" events="687" subjects_affected="166" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="162" subjects_affected="147" subjects_at_risk="2390"/>
                <counts group_id="E2" events="44" subjects_affected="39" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="306" subjects_affected="276" subjects_at_risk="2390"/>
                <counts group_id="E2" events="54" subjects_affected="48" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2586" subjects_affected="1355" subjects_at_risk="2390"/>
                <counts group_id="E2" events="402" subjects_affected="217" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4497" subjects_affected="1816" subjects_at_risk="2390"/>
                <counts group_id="E2" events="717" subjects_affected="298" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

